Skip to content

Study · Animal study (in vivo) · mouse · 2012

10 results

Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis.

Suzuki J, Yoshimura T, Simeonova M, Takeuchi K, Murakami Y, Morizane Y, Miller JW, Sobrin L, Vavvas DG

Investigative ophthalmology & visual science28 Jun 2012Cited by 34 (Europe PMC)

PMID22562518 (opens in a new tab)PMCIDPMC3392008 (opens in a new tab)DOI10.1167/iovs.11-9323 (opens in a new tab)PepBankPUB-22562518
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAU, AICAR significantly reduced clinical disease severity.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR reduced clinical disease severity.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseClinical EAU severity
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    AICAR treatment significantly reduced clinical and histologic severity of EAU as well as ocular cytokine production.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAU, AICAR significantly reduced histologic disease severity.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR reduced disease severity in tissue examinations.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseHistologic EAU severity
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    AICAR treatment significantly reduced clinical and histologic severity of EAU as well as ocular cytokine production.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with EAU, AICAR significantly reduced ocular cytokine production.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR reduced cytokine production in the eyes.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseOcular cytokine production
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Inflammation markers · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    AICAR treatment significantly reduced clinical and histologic severity of EAU as well as ocular cytokine production.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In the mouse EAU study, the AICAR-associated anti-inflammatory effect involved inhibition of T-cell proliferation.

    In plain wordsIn mice with autoimmune eye inflammation, the AICAR-associated anti-inflammatory effect involved reduced T-cell proliferation.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseT-cell proliferation
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    An anti-inflammatory effect associated with the inhibition of T-cell proliferation and Th1 and Th17 cytokine production was observed.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In the mouse EAU study, AICAR-associated anti-inflammatory effects involved inhibition of Th1 cytokine production.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR-associated effects involved reduced Th1 cytokine production.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseTh1 cytokine production
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    An anti-inflammatory effect associated with the inhibition of T-cell proliferation and Th1 and Th17 cytokine production was observed.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In the mouse EAU study, AICAR-associated anti-inflammatory effects involved inhibition of Th17 cytokine production.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR-associated effects involved reduced Th17 cytokine production.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseTh17 cytokine production
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    An anti-inflammatory effect associated with the inhibition of T-cell proliferation and Th1 and Th17 cytokine production was observed.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with EAU, an increase in the Th2 response was not observed with AICAR treatment.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR treatment did not produce an observed increase in the Th2 response.

    Peptide
    AICAR (acadesine)
    Outcome
    Direction not reportedTh2 response
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    Increases in the Th2 response and Treg population were not observed with AICAR treatment.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with EAU, an increase in the Treg population was not observed with AICAR treatment.

    In plain wordsIn mice with autoimmune eye inflammation, AICAR treatment did not produce an observed increase in regulatory T cells.

    Peptide
    AICAR (acadesine)
    Outcome
    Direction not reportedTreg population
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune uveoretinitis
    Outcome group
    Immune response · Eye
    Studied dose
    200 mg/kg daily · intraperitoneal · day 0 until day 21As given in this study (mouse).

    Source sentences

    Summary
    Increases in the Th2 response and Treg population were not observed with AICAR treatment.
    1 context sentence
    Summary · context
    C57BL/6 mice were injected daily with AICAR (200 mg/kg, intraperitoneally [IP]) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, until day 21.
  9. 09LabIn vitro (cells)Mechanism

    In mouse bone marrow-derived dendritic cells, AICAR significantly inhibited maturation.

    In plain wordsIn cells, AICAR inhibited maturation of mouse bone marrow-derived dendritic cells.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseBMDC maturation
    Study

    mousen: not reported in source

    mouse bone marrow-derived dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AICAR did significantly inhibit BMDC maturation by reducing co-stimulatory molecule expression.
  10. 10LabIn vitro (cells)Mechanism

    In mouse bone marrow-derived dendritic cells, AICAR reduced co-stimulatory molecule expression.

    In plain wordsIn cells, AICAR reduced co-stimulatory molecule expression in mouse bone marrow-derived dendritic cells.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseCo-stimulatory molecule expression
    Study

    mousen: not reported in source

    mouse bone marrow-derived dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AICAR did significantly inhibit BMDC maturation by reducing co-stimulatory molecule expression.
    1 context sentence
    Summary · context
    Co-stimulatory molecule expression (CD40, 80, 86, and I-Ab) on dendritic cells (DCs) in EAU and on bone marrow-derived dendritic cells (BMDCs) treated with AICAR was measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.